According to filings with the U.S. Securities and Exchange Commission, Aeovian Pharmaceuticals is raising up to $50,415,077.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Allison Hulme played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aeovian Pharmaceuticals
We are a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases. Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Our lead development candidate, AV078, is a first-in-class CNS penetrant selective mTORC1 inhibitor being developed for the treatment of tuberous sclerosis complex (TSC) refractory epilepsy and is currently being evaluated in a Phase 1 trial. TSC is a rare genetic disorder caused by the hyperactive signaling of mTORC1. Beyond AV078, we have developed a proprietary library of small molecules, which are potent and selective inhibitors of either mTORC1 or CD38 and have the potential to precisely target the underlying biology of multiple rare and age-related diseases.

To learn more about Aeovian Pharmaceuticals, visit http://www.aeovian.com/

Contact:
Allison Hulme, Chief Executive Officer
415-209-2055
https://www.linkedin.com/in/allison-hulme-14123b24/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.